• Published on: Apr 04, 2020
  • 3 minute read
  • By: Dr Rajan Choudhary

Developing A Vaccine For COVID-19? Part 1

  • WhatsApp share link icon
  • copy & share link icon
  • twitter share link icon
  • facebook share link icon

It is often stated vaccination has made the greatest contribution to global health of any human discovery, other than clean water and sanitation, and their impact on everyday life is immediately evident. We have managed to completely eradicate two major infections from existence (smallpox and rinderpest) , and the WHO are working towards adding polio to that list.

In these cases the numbers speak for themselves. It is estimated that the eradication of smallpox in 1980 has saved 5 million lives per year, adding up to 150 to 200 million by 2018. Common vaccination programmes for polio, measles, mumps, rubella, rabies and hepatitis A have prevented nearly 200 million cases from occurring in the US alone over the past 50 years, and 4.5 billion instances of the diseases worldwide.

We have achieved a 99% immunisation rate against polio, preventing children from suffering crippling paralysis, and only 3 countries remain. Sadly, around 1.4 million children under 5 still die from preventable diseases each year as they do not have access to these life saving vaccines, but charities and public health organisations around the world are working hard to improve access.

So what are vaccines? And how will they help is in the face of the latest pandemic? Here we will go into the challenges behind making vaccines, and why a vaccine against COVID-19 is unlikely to be ready in the next few months, or even this year.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024226/ contribution of vaccination

https://www.who.int/features/factfiles/polio/en/ polio eradication

https://www.sciencedaily.com/releases/2017/03/170303163208.htm study article

WHAT IS A VACCINE

The human body’s immune system is incredibly smart. It is able to distinguish between infective organisms, such as bacteria, viruses and parasites, from our own body’s cells, target these invaders for destruction and keep our bodies healthy. Even better, the body remembers any previous infections it has had before, recognise these previous infections even quicker and even eradicate the disease before we know we are infected.

Vaccines target the immune system’s memory by presenting them with pieces of these infective diseases. The small amounts do not cause any infective symptoms, but if the person is infected later in life their body will mount a quicker response and prevent them from falling ill. These vaccines can contain broken up parts of the organisms, “dead” organisms or “live” versions that have been severely weakened so they cannot cause any harm.

In summary, medicines treat us when we get an infection. Vaccines make sure we never suffer from an infection in the first place.

https://www.chop.edu/centers-programs/vaccine-education-center/making-vaccines/how-are-vaccines-made Making Vaccines

THE HURDLES WE FACE IN RESEARCH

Making a vaccine is a difficult process, one that can take 3–5 years and cost hundreds of millions of dollars, sometimes billions of dollars. This is because there are many difficult steps to be taken in the process of creating a vaccine that is effective, but more importantly one that is safe.

To start with the troubling organism has to be identified. For COVID-19 it took a few weeks to recognise the virus responsible, and some time more to understand its genetic code and grow the virus in lab conditions. We then have to understand the virus, how it infects, how it causes symptoms, and how it has mutated compared to the coronaviruses responsible for SARS and MERS.

After this, we have to isolate parts of the virus our immune system will recognise. This is usually the outside coat of the virus. The DNA responsible for making these parts need to be found in the virus’ genetic code, and put inside other “skeleton” viruses. This will force the dummy virus to look like coronavirus, without the ability to infect and kill someone.

These dummy viruses can be injected into animals to see if it causes an immune reaction, whether the immune system recognises it as the coronavirus responsible for COVID-19, and whether it will protect the animal from the real COVID-19. Up to now the research has likely cost a few million dollars. The next step is when the price inflates up to billions.

If the vaccine appears safe in animals, it can be tested in humans. This can be dangerous at first, since we don’t know whether a vaccine that works in an animal will work in a human. And we don’t know if there will be any side effects to the vaccine. Human testing has to be very thorough, very careful, and safe for use. If you give too much of the virus it might make the person sick, too little and it wont immunise the person. These clinical trials can take years, and if the vaccine fails at this point its back to the drawing board, to try another step.

https://www.theatlantic.com/politics/archive/2014/10/how-to-make-an-ebola-vaccine-5-simplified-steps/454443/ ebola vaccine

Now we have a basic understanding of what vaccines are and why it takes so long to make a vaccine. In the next part we will look at why viral vaccines can cause even more problems, and how far we have come with the COVID-19 vaccine,

Dr Rajan Choudhary, London UK

Read Blog
Monkeypox

Monkeypox Virus Symptoms: Early Signs, Disease Progression, and When to Seek Care

Monkeypox, now commonly referred to as mpox, is a viral infection that has gained global attention due to outbreaks beyond traditionally affected regions. Understanding monkeypox virus symptoms is essential for early detection, timely isolation and prevention of further spread.

According to the World Health Organization and Indian public health authorities, awareness of symptom patterns plays a critical role in controlling outbreaks and protecting vulnerable populations.

What Is the Monkeypox Virus?

Monkeypox is caused by the monkeypox virus, a member of the Orthopoxvirus family, which also includes smallpox. While generally less severe than smallpox, monkeypox can still cause significant illness and discomfort.

The virus spreads primarily through close physical contact.

 

Incubation Period of Monkeypox

After exposure, symptoms typically appear within:

  • 5 to 21 days

  • most commonly 6 to 13 days

Individuals may feel well during this period but can become infectious once symptoms begin.

 

Early Monkeypox Virus Symptoms

Fever

Fever is usually the first symptom and may be:

  • sudden in onset

  • moderate to high grade

  • accompanied by chills

Fever signals the start of systemic infection.

 

Headache and Body Aches

Patients often experience:

  • severe headache

  • muscle aches

  • back pain

These symptoms resemble many viral illnesses.

 

Fatigue and Weakness

Marked tiredness and low energy levels are common and may limit daily activities.

 

Swollen Lymph Nodes

Swollen lymph nodes are a distinguishing feature of monkeypox.

Common sites include:

  • neck

  • armpits

  • groin

This helps differentiate monkeypox from chickenpox or smallpox.

Development of Monkeypox Rash

The skin rash usually appears:

  • 1 to 3 days after fever onset

It may begin on the face or genital area and spread to other parts of the body.

 

Stages of Monkeypox Rash

The rash progresses through well-defined stages:

Macules

Flat red spots on the skin.

Papules

Raised, firm bumps.

Vesicles

Fluid-filled blisters.

Pustules

Pus-filled lesions that are painful.

Scabs

Lesions crust over and eventually fall off.

Complete healing occurs once scabs detach.

 

Distribution of Rash

Rash commonly affects:

  • face

  • hands and feet

  • mouth

  • genital and anal areas

The number of lesions can vary widely.

 

Pain and Discomfort

Rash lesions may be:

  • painful

  • itchy during healing

Pain severity differs between individuals.

 

Other Possible Symptoms

Additional symptoms may include:

  • sore throat

  • cough

  • nasal congestion

These reflect upper respiratory involvement.

 

Duration of Illness

Monkeypox symptoms typically last:

  • 2 to 4 weeks

Recovery occurs gradually as lesions heal.

 

Who Is at Higher Risk of Severe Illness?

Higher risk groups include:

  • children

  • pregnant women

  • individuals with weakened immunity

  • people with chronic illness

Early care is crucial in these groups.

 

Complications of Monkeypox

Though uncommon, complications may include:

  • secondary bacterial skin infections

  • dehydration

  • pneumonia

  • eye involvement

Prompt medical guidance reduces risk.

 

How Monkeypox Is Transmitted

Transmission occurs through:

  • direct skin-to-skin contact

  • contact with lesions or bodily fluids

  • respiratory droplets during close contact

  • contaminated clothing or bedding

Understanding transmission helps prevent spread.

 

When to Seek Medical Care

Seek medical evaluation if:

  • fever is followed by rash

  • lymph nodes become swollen

  • rash appears in genital or facial areas

Early diagnosis supports isolation and care.

 

Diagnosis and Testing

Diagnosis may involve:

  • clinical examination

  • laboratory testing of lesion samples

Public health authorities guide testing protocols.

 

Prevention and Control Measures

Preventive steps include:

  • avoiding close contact with infected individuals

  • maintaining good hand hygiene

  • isolating during illness

  • following public health guidance

Vaccination may be recommended for high-risk groups.

 

Role of Public Awareness

Awareness of symptoms:

  • enables early detection

  • reduces stigma

  • supports timely care

WHO emphasises community education in outbreak control.

 

Conclusion

Monkeypox virus symptoms typically begin with fever, body aches and swollen lymph nodes, followed by a characteristic rash that progresses through defined stages. While most cases are self-limiting, early recognition, medical evaluation and isolation are essential to prevent complications and reduce transmission. Staying informed and acting promptly protects both individual and public health.

 

References

  • World Health Organization (WHO) – Mpox (Monkeypox) Clinical and Public Health Guidance

  • Indian Council of Medical Research (ICMR) – Emerging Viral Infections Reports

  • National Centre for Disease Control (NCDC), India – Monkeypox Advisories

  • Lancet – Clinical Features and Outcomes of Mpox

  • NITI Aayog – Public Health Preparedness and Infectious Disease Control

See all

Live Doctor consultation
Live Doctor Chat

Download Our App & Get Consultation from anywhere.

App Download
call icon for mobile number calling and whatsapp at secondmedic